SCHEMBL29415410

SCHEMBL29415410

N#Cc1cncnc1Oc1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.51
▸ KMT2A Q03164 7/20 0.51
▸ KDM4E B2RXH2 6/20 0.51
▸ HPGD P15428 5/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CYP1A2 P05177 4/20 0.44
▸ CYP2C19 P33261 3/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP3A4 P08684 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ PIN1 Q13526 1/20 0.42
▸ TRPA1 O75762 1/20 0.42
▸ MRGPRX1 Q96LB2 1/20 0.40
▸ SLC22A12 Q96S37 2/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16822091 0.84 CYP1A2 (0.47) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL29719546 0.76 KMT2A (0.56) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL31395363 0.76 TRPA1 (0.49) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL16822015 0.72 CYP11B1 (0.46) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL6611000 0.71 PTGER4 (0.46) MEN1KMT2A
SCHEMBL29531043 0.71 PRKCQ (0.39) MEN1KMT2AKDM4EALDH1A1PIN1
SCHEMBL27300783 0.70 CYP1A2 (0.55) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL12634621 0.68 SLC22A12 (0.45) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL27761280 0.68 SOS1 (0.48) MEN1KMT2AKDM4EALDH1A1CYP3A4
SCHEMBL6160870 0.68 MEN1 (0.58) MEN1KMT2AKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA MEN1 1532/4885KMT2A 2721/4885KDM4E 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback